Lonza Pharma & Biotech announced the establishment of a Center of Excellence for Dry Powder Inhaler (DPI) drug product development at its Bend (OR) USA site. The DPI service offer leverages the particle engineering expertise and capabilities at Lonza-Bend while incorporating Lonza site network capabilities where applicable for specific customers and/or drug programs. The core service offer is comprised of a head-to-head evaluation of particle engineering approaches (spray drying and micronization), along with capsule-based DPI formulation design and development.
Utilizing phase-appropriate assets, Lonza scientists can provide capsule-based DPI formulations for feasibility studies in as little as 12 weeks. Analytical services, including initial stability studies, are also available as part of the DPI service package. The service package can be further tailored to individual drug programs with drug substance development and supply, and services for regulatory filing submissions.
“Drug delivery via the lung is an increasingly viable treatment option for a number of therapeutic areas. We have determined a growing market need for service partners that have both particle engineering expertise as well as integrated product development solutions that can effectively advance customer molecules utilizing the DPI format while minimizing program risk and complexity,” Christian Dowdeswell, SVP Lonza Pharma and Biotech said.
“The key challenge for respiratory delivery remains the ability to engineer stable drug particles. We provide DPI formulation services based on our vast experience in particle engineering, formulation design and encapsulation techniques tailored to the target product profile and delivery device,” Quote from Herbert Chiou, Subject Matter Expert – DPI Formulations said.